title: First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization.
abstract: OBJECTIVE
  To report the first pregnancy and live birth after ovarian stimulation using a chimeric long-acting human recombinant FSH agonist (recFSH-CTP) for IVF.
  
  
  METHODS
  Case report.
  
  
  METHODS
  Tertiary fertility center.
  
  
  METHODS
  A 32-year-old woman with a 7-year history of primary infertility.
  
  
  METHODS
  Ovarian stimulation with a single SC injection of 180 microg recFSH-CTP on cycle day 3, followed by daily injections of 150 IU recFSH from cycle day 10 onward, combined with daily GnRH antagonist 0.25 mg SC to prevent a premature LH rise. Final oocyte maturation was induced by 10,000 IU hCG.
  
  
  METHODS
  First ongoing pregnancy obtained with recFSH-CTP.
  
  
  RESULTS
  Twelve oocytes were retrieved. Ten oocytes were fertilized in vitro by intracytoplasmic sperm injection, and from these 10 oocytes, two embryos were subsequently transferred after 3 days of culture. A pregnancy test 2 weeks after ET was positive, and ultrasound investigation revealed an intact, intrauterine, singleton pregnancy after 12 weeks.
  
  
  CONCLUSIONS
  The first pregnancy and live birth was achieved after ovarian stimulation using recFSH-CTP for IVF.
authors.affiliation: Center for Reproductive Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Nicole G M
authors.initials: NG
authors.lastname: Beckers
authors.forename: Nicholas S
authors.initials: NS
authors.lastname: Macklon
authors.forename: Paul
authors.initials: P
authors.lastname: Devroey
authors.forename: Peter
authors.initials: P
authors.lastname: Platteau
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Boerrigter
authors.forename: Bart C J M
authors.initials: BC
authors.lastname: Fauser
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004624:Embryo Transfer; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D043373:Follicle Stimulating Hormone, Human; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D006727:Hormone Antagonists / Q000008:administration & dosage; D006801:Humans; D007247:Infertility, Female / Q000628:therapy*; D007279:Injections, Subcutaneous; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011994:Recombinant Proteins / Q000627:therapeutic use; D020554:Sperm Injections, Intracytoplasmic
chemical_list: D006063:Chorionic Gonadotropin; D043373:Follicle Stimulating Hormone, Human; D006727:Hormone Antagonists; D011994:Recombinant Proteins; C437186:follicle stimulating hormone, human, with HCG C-terminal peptide; D007987:Gonadotropin-Releasing Hormone; D005640:Follicle Stimulating Hormone; C061018:ganirelix